Yea it's crazy how low the MC is, just doesn't make any sense.
Even with the slow/paused trials and high cost/low cash issue, CHM should be valued higher. Some other biotechs have no clinical assets, some failing pre-cinical hurdles such as manufacturing or safety and yet have similar market caps to CHM.
All the same, this announcement is probably more bad news than good, for me. Yes, another AML CR, but this tiny 12 patient trial could take another 2-3 years at this rate.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)